The lack of diversity in clinical trials has been a topic of debate for decades, but was thrust into the spotlight as the impact of the pandemic on poorer, less educated, and ethnically div
Now that the COVID-19 pandemic has provided the industry with a solid foundation of experience with decentralised trials, it is appropriate to reflect and ask whether DCT studies are truly
Despite randomised clinical trials (RCTs) being the gold standard for drug approval studies, the shift towards precision medicine has increased the use of single-arm trials (SATs).
It’s often stated - mostly without reference to data - that the environment for innovative launches is more competitive now than it ever has been. Is this true?
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
